Supplements · Sweeteners · Metabolic & Cardiometabolic
stevia decreases blood pressure
In plain terms: Does stevia lower blood pressure?
Part of: • Stevia
Only at doses far higher than you'd ever sweeten food with. The blood-pressure results come from giving hypertensive patients gram-level doses of stevioside - basically using it as a drug - and even those studies nearly all come from one research group. At normal tabletop amounts, stevia does nothing to blood pressure.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
The blood-pressure claim is real but dose-dependent, and doesn't apply to everyday use. The positive results come from older trials giving gram-level pharmacological doses of stevioside (750–1500 mg/day) to hypertensive patients — and nearly all of them trace to a single, non-independent East-Asian research cluster.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hsieh MH et al. 2003 · Clin Ther | RCT | mixed | moderate | 2-yr RCT (174 mild hypertension): stevioside 1500 mg/d lowered SBP/DBP. [high dose; SAME research cluster as Chan - not independent] |
| Chan P et al. 2000 · Br J Clin Pharmacol | RCT | supports | moderate | 1-yr RCT (106 Chinese hypertensives): stevioside 750 mg/d lowered SBP/DBP vs placebo. [high pharmacological dose; single research cluster] |
| Rizwan F et al 2025 · study_type: RCT | RCT | mixed | low | Stevia 250mg BID (therapeutic dose) in CKD Stage I-III patients: SBP p<0.043, DBP p<0.001 reduction at 9mo; reverted toward baseline during washout (no stevia). |
| Jeppesen PB et al. 2003 · Metabolism | animal | supports | low | Diabetic rats: stevioside lowered systolic and diastolic BP - mechanism/plausibility, not human proof. |
| Ayoub-Charette S et al. 2025 · Am J Clin Nutr | meta-analysis | mixed | moderate | Bias-adjusted umbrella review (LNCS class): modest SBP reduction vs comparators at ordinary intake - NNS-class, not stevia-isolated. |
| Onakpoya IJ, Heneghan CJ 2015 · Eur J Prev Cardiol | meta-analysis | mixed | moderate | SR/meta: pooled BP reduction in hypertensives BUT flags high risk of bias, small trials, same research groups, dose-dependence. |
| Bundgaard Anker CC et al. 2019 · Nutrients | meta-analysis | mixed | moderate | SR/meta: BP effects inconsistent and dose-dependent; no robust benefit at typical consumption levels. |
| Barriocanal LA et al. 2008 · Regul Toxicol Pharmacol | RCT | contradicts | moderate | RCT at sweetener dose (250 mg TID): NO significant change in SBP/DBP in any group - 'apparent lack of pharmacological effect'. |
| Ferri LA et al. 2006 · Phytother Res | RCT | contradicts | moderate | RCT (mild hypertensives): crude stevioside up to 15 mg/kg/d showed NO antihypertensive effect beyond placebo (both fell). [moderate/culinary-comparable dose] |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.